Mesoblast’s (MESO) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Mesoblast (NASDAQ:MESO) in a research report released on Friday morning,Benzinga reports. Piper Sandler currently has a $24.00 price objective on the stock, up from their previous price objective of $15.00.

Several other equities analysts have also weighed in on the stock. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Cantor Fitzgerald raised shares of Mesoblast to a “strong-buy” rating in a report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Stock Up 4.3 %

Mesoblast stock opened at $19.49 on Friday. The business’s 50-day moving average price is $16.33 and its 200 day moving average price is $10.92. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. Mesoblast has a 52 week low of $1.75 and a 52 week high of $22.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Prosperity Wealth Management Inc. raised its position in Mesoblast by 2.0% during the fourth quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock worth $1,846,000 after acquiring an additional 1,795 shares during the period. Lindbrook Capital LLC increased its stake in shares of Mesoblast by 70.9% during the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company’s stock worth $43,000 after purchasing an additional 901 shares in the last quarter. Pine Valley Investments Ltd Liability Co raised its position in shares of Mesoblast by 78.7% during the 4th quarter. Pine Valley Investments Ltd Liability Co now owns 20,931 shares of the company’s stock worth $414,000 after purchasing an additional 9,217 shares during the last quarter. Strategic Financial Concepts LLC acquired a new position in shares of Mesoblast during the 4th quarter worth about $2,744,000. Finally, Sageworth Trust Co purchased a new position in Mesoblast in the 4th quarter valued at about $198,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.